CN Patent

CN119386015A — 用于治疗高血压的组合物

Assigned to George Institute for Global Health · Expires 2025-02-07 · 1y expired

What this patent protects

本文提供了可用于治疗高血压的药物组合物，其包含血管紧张素II受体阻滞剂、利尿剂和钙通道阻滞剂。这些组合物以每种药剂的最低高血压治疗剂量(LHTD)的40‑80％的剂量施用。本申请还涉及包含替米沙坦、噻嗪样利尿剂和钙通道阻滞剂的组合物，其以每种药剂的LHTD的80‑150％的剂量施用。

USPTO Abstract

本文提供了可用于治疗高血压的药物组合物，其包含血管紧张素II受体阻滞剂、利尿剂和钙通道阻滞剂。这些组合物以每种药剂的最低高血压治疗剂量(LHTD)的40‑80％的剂量施用。本申请还涉及包含替米沙坦、噻嗪样利尿剂和钙通道阻滞剂的组合物，其以每种药剂的LHTD的80‑150％的剂量施用。

Drugs covered by this patent

Patent Metadata

Patent number
CN119386015A
Jurisdiction
CN
Classification
—
Expires
2025-02-07
Drug substance claim
No
Drug product claim
No
Assignee
George Institute for Global Health
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.